“Comel” invests $1.38 million in the American “Cure Sales”.
Company Board of Directors approved "coml"Yesterday, Sunday, it agreed to invest in the American company (Kure Cells), a company working in biotechnology, cell therapies and regenerative medicine, at a value of $1.38 million (5.18 million riyals).
She explained. "coml" In a statement on "Saudi Arabia trading"Today, Monday, it announced that, under the investment, it will own 1.3% of the company’s ownership (non-controlling share), while the share price is $49, with the company covering the investment from its own resources.
This investment aims to direct Comel to invest in developing advanced therapeutic products and technologies with increasing demand and a promising market, in line with the company’s strategy.
/>
Cure Cells is an American company (Delaware state law after reincorporation) and is a pioneering company in the field of biotechnology, working in the development of cell-based therapies and technologies within the field of regenerative medicine, with its focus on rapid manufacturing platforms for CAR-T treatments and research therapeutic programs in oncology.
She noted "coml" No immediate material impact is expected from this investment, and any future impact – if any – will appear according to the performance of the target company and the development of investment in it, and any fundamental developments in this regard will be disclosed.
- For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter
